Home > Neurology > ECTRIMS 2021 > Progressive MS > Ocrelizumab shows long-term benefits in primary progressive MS

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By
Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA
Conference
ECTRIMS 2021
Trial
Phase 3, ORATORIO
Patients with primary progressive MS (PPMS) who were originally receiving ocrelizumab had a lower risk of disability progression than patients originally receiving placebo after 8-years of follow-up, despite later cross-over in the open-label extension (OLE) period of the phase 3 ORATORIO trial. In addition, patients originally receiving ocrelizumab had a significantly reduced rate of recurrent 48-week confirmed disability progression (CDP) events, compared with participants who received ocrelizumab only later in the trial [1]. Ocrelizumab outperformed placebo in patients with PPMS in the 144-week, double-blind plus extended controlled periods of the randomised, phase 3 ORATORIO trial (NCT01194570). The OLE of this trial assessed the long-term efficacy and safety of ocrelizumab for...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on